Labcorp and Medidata, a subsidiary of Dassault Systèmes, have expanded their strategic collaboration to offer a suite of clinical trial technologies and services.
Under the partnership, Labcorp will utilise Medidata’s technology platform to extend the usage and functionality of decentralised clinical trials and jointly develop digital biomarkers.
Beginning with Rave electronic data capture (EDC), Coder and targeted source data verification (TSDV), Labcorp Drug Development has built its offerings on Medidata technologies.
Currently, Labcorp leverages most of the Clinical Cloud platform of Medidata, including randomisation and trial supply management (RTSM), electronic clinical outcome assessment (eCOA) and Imaging.
Labcorp Drug Development Clinical Therapeutic and Regulatory Sciences chief scientific officer and president Bill Hanlon said: “Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentralised clinical trial offerings.
“Our work to advance sensor and digital biomarker usage in clinical research can help accelerate patient care while providing valuable information to study sponsors.”
Medidata helps in producing the data and insights to aid pharmaceutical, biotech and academic institutes to expedite value, reduce risk and enhance outcomes.
Medidata Patient Cloud CEO Anthony Costello said: “The last two years have required clinical trials to become more accessible and flexible; these changes make our strategic partnership with Labcorp Drug Development to modernise and decentralise trials even more critical.
“With this new agreement, we’re excited to develop and deploy the innovations that help our customers run more effective clinical programmes and get new treatments to patients faster than ever before.”
In February this year, Medidata announced the offering of its Patient Centricity by Design process for clinical trials to sponsors, contract research organisations and sites.
The Patient Insights Program of the company will be made available under the offering that will include a patient-centric approach to design and develop trial protocols and technologies.